Biosimilar Competition and Payments in Medicare: The Case of Trastuzumab.
Danea Marie HornAbby E AlpertMark G DugganNicolas A GarciaMireille JacobsonPublished in: JCO oncology practice (2023)
Biosimilar entry may be an effective means of decreasing the cost of biologic cancer treatments. Our findings suggest that policies that support biosimilar entry and encourage use may expand access to necessary treatment and reduce health care costs.